Atrial Fibrillation After Radiofrequency Ablation of Type I Atrial Flutter

Objective To investigate the safety of radiofrequency ablation for reducing inflammatory cytokines and the left atrial diameter in patients with atrial fibrillation (AF). Methods A total of 200 patients with AF who were admitted to our hospital from December 2015 to April 2017 were included in this prospective analysis. Fifty patients were treated with conventional AF medication alone (AF medication group) and 50 patients received radiofrequency ablation (RFA) on the basis of conventional medication (RFA group). Results After treatment, the AF medication group showed significantly higher levels of high-sensitivity C-reactive protein, interleukin-6, carboxyterminal propeptide of type-I procollagen, procollagen type III N-terminal propeptide, and matrix metallopeptidase-9 than the RFA group. The AF medication group had a significantly lower activated partial thromboplastin time, thrombin time, and prothrombin time than the RFA group. A significantly smaller left atrial diameter was observed in both groups after treatment, but this decrease was more pronounced in the RFA group than in the AF medication group. The total treatment efficacy rate was significantly lower in the AF medication group than in the RFA group. Conclusions For patients with AF, RFA leads to a lower incidence of inflammatory responses, faster recovery of cardiac function, and good safety.

Download Full-text

Radiofrequency ablation of atypical atrial flutter after cardiac surgery or atrial fibrillation ablation: A randomized comparison of open-irrigation-tip and 8-mm-tip catheters

Heart Rhythm ◽

10.1016/j.hrthm.2007.07.027 ◽

2007 ◽

Vol 4 (12) ◽

pp. 1489-1496 ◽

Cited By ~ 10

Author(s):

Rong Bai ◽

Tamer S. Fahmy ◽

Dimpi Patel ◽

Luigi Di Biase ◽

Lucie Riedlbauchova ◽

...

Keyword(s):

Atrial Fibrillation ◽

Cardiac Surgery ◽

Radiofrequency Ablation ◽

Atrial Flutter ◽

Atrial Fibrillation Ablation

Download Full-text

Acute and long-term results of radiofrequency ablation of common atrial flutter and the influence of the right atrial isthmus ablation on the occurrence of atrial fibrillation

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(03)81025-2 ◽

2003 ◽

Vol 41 (6) ◽

pp. 95

Author(s):

Sebastian Schmieder ◽

Gjin Ndrepepa ◽

Jun Dong ◽

Bernhard Zrenner ◽

Juergen Schreieck ◽

...

Keyword(s):

Atrial Fibrillation ◽

Radiofrequency Ablation ◽

Atrial Flutter ◽

Right Atrial ◽

Long Term Results ◽

The Right

Download Full-text

RIVOROXABAN IN PATIENTS WITH TYPE I ATRIAL FLUTTER: EFFECTIVENESS, SAFETY AND COMPLIANCE

Complex Issues of Cardiovascular Diseases ◽

10.17802/2306-1278-2018-7-3-44-55 ◽

2018 ◽

Vol 7 (3) ◽

pp. 44-55

Author(s):

A. V. Fedoseenko ◽

S. A. Zenin ◽

O. V. Kononenko ◽

O. V. Pyataeva ◽

Y. E. Voskoboyniokov

Keyword(s):

Atrial Fibrillation ◽

Risk Assessment ◽

Atrial Flutter ◽

Bleeding Risk ◽

Control Group ◽

Type I ◽

Adherence To Treatment ◽

High Adherence ◽

Potential Benefits ◽

Atrial Fibrillation Group

Aim. To assess effectiveness, safety and adherence to treatment of patients with type I atrial flutter who were previously excluded from the clinical trials evaluating the potential benefits of rivoroxaban for thromboembolism prevention.Methods. 27 medical records of patients with type I atrial flutter were retrospectively reviewed and assigned to the study group. The control group consisted of 100 patients with atrial fibrillation. Both groups received rivoroxaban. All patients underwent thromboembolism risk assessment with the CHA2DS2-VACs score, bleeding risk assessment with HAS-BLED score. Data were collected by telephone.Results. No thromboembolic events were registered in the atrial flutter group, whereas one case of ischemic stroke was in the atrial fibrillation group. There were no major bleedings in both groups. Four patients with atrial flutter and 2 patients with atrial fibrillation had hemorrhages. Patients’ adherence to rivoroxaban was 75–80%.Conclusion. Rivoroxaban therapy was found to be effective and safe in patients with type I atrial flutter including those who underwent cardioversion. High adherence to rivoroxaban therapy was demonstrated.

Download Full-text

Predictors of Failure Cardioversion for Recurrent Atrial Fibrillation Following Mitral Valve Surgery With Ablation

The Heart Surgery Forum ◽

10.1532/hsf.2997 ◽

2020 ◽

Vol 23 (3) ◽

pp. E300-E304

Author(s):

Hailong Cao ◽

Xin Chen ◽

Xiyu Zhu ◽

Yining Yang ◽

Qing Zhou ◽

...

Keyword(s):

Atrial Fibrillation ◽

Radiofrequency Ablation ◽

Mitral Valve ◽

Atrial Flutter ◽

Left Atrial ◽

Mitral Valve Surgery ◽

Valve Surgery ◽

Loading Dose ◽

Left Atrial Diameter ◽

Recurrent Atrial Fibrillation

Background: Electrical cardioversion (ECV) often is required for terminating recurrent atrial fibrillation (AF) after surgical radiofrequency ablation in patients undergoing mitral valve surgery. However, ECV is unsuccessful in some cases. In this study, we aimed to identify possible predictors of failed ECV for recurrent atrial fibrillation following mitral valve surgery with concomitant radiofrequency ablation. Methods: We enrolled 1,136 persistent AF patients with history of mitral valve surgery and concomitant radiofrequency ablation. Three-hundred-nineteen patients experienced recurrence of persistent AF and received ECV therapy. Comparison was made between patients with failed ECV (Failure group, N = 68) and successful ECV (Success group, N = 251). Results: In multivariate regression analysis, age, pre-ECV loading-dose amiodarone, left atrial diameter, atrial flutter and time from surgery to ECV were independent predictors for outcomes of ECV. According to receiver operating characteristic curve analysis, the best threshold values of age, left atrial diameter and time from surgery to ECV for predicting failed ECV were 55.5 years, 64.5 mm, and 90.5 days, respectively. Conclusion: Older age, larger left atrium and longer time from surgery to ECV are independent predictors for failed ECV in this group. Compared with AF, atrial flutter is easier to be successfully terminated by ECV. Pre-ECV loading-dose amiodarone is helpful for successful ECV. These findings have important implications for identifying the kinds of patients to receive effective ECV.

Download Full-text